Sonoma Pharmaceuticals, Inc.

Equities

SNOA

US83558L2043

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 25/06/2024 BST 5-day change 1st Jan Change
0.1899 USD +0.05% Intraday chart for Sonoma Pharmaceuticals, Inc. -1.09% +5.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference CI
Sector Update: Health Care Stocks Ease in Late Afternoon MT
Sector Update: Health Care MT
Top MIdday Decliners MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected MT
Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target MT
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board CI
Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller CI
Earnings Flash (SNOA) SONOMA PHARMACEUTICALS Reports Q4 Revenue $3M MT
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Sonoma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
Top Premarket Gainers MT
Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union CI
Sonoma Pharmaceuticals, Inc. Announces CFO Changes CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sonoma Pharmaceuticals Signs Distribution Deal With Daewoong Pharmaceutical to Sell Skin Products in South Korea MT
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea CI
Chart Sonoma Pharmaceuticals, Inc.
More charts
Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1899 USD
Average target price
1.5 USD
Spread / Average Target
+689.89%
Consensus
  1. Stock Market
  2. Equities
  3. SNOA Stock
  4. News Sonoma Pharmaceuticals, Inc.
  5. Sector Update: Health Care Stocks Ease in Late Afternoon